These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31517670)

  • 21. Augmented and doubly robust G-estimation of causal effects under a Structural nested failure time model.
    Mertens K; Vansteelandt S
    Biometrics; 2018 Jun; 74(2):472-480. PubMed ID: 28742252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimating population treatment effects from a survey subsample.
    Rudolph KE; Díaz I; Rosenblum M; Stuart EA
    Am J Epidemiol; 2014 Oct; 180(7):737-48. PubMed ID: 25190679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Causal inference for recurrent event data using pseudo-observations.
    Su CL; Platt RW; Plante JF
    Biostatistics; 2022 Jan; 23(1):189-206. PubMed ID: 32432686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variance estimation for the average treatment effects on the treated and on the controls.
    Matsouaka RA; Liu Y; Zhou Y
    Stat Methods Med Res; 2023 Feb; 32(2):389-403. PubMed ID: 36476035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating multiple surrogate markers with censored data.
    Parast L; Cai T; Tian L
    Biometrics; 2021 Dec; 77(4):1315-1327. PubMed ID: 32920821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doubly-robust estimator of the difference in restricted mean times lost with competing risks data.
    Lin J; Trinquart L
    Stat Methods Med Res; 2022 Oct; 31(10):1881-1903. PubMed ID: 35607287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data.
    Pullenayegum EM; Willan AR
    Stat Med; 2007 Jul; 26(17):3274-99. PubMed ID: 17309112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AIPW: An R Package for Augmented Inverse Probability-Weighted Estimation of Average Causal Effects.
    Zhong Y; Kennedy EH; Bodnar LM; Naimi AI
    Am J Epidemiol; 2021 Dec; 190(12):2690-2699. PubMed ID: 34268567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On variance estimation of target population created by inverse probability weighting.
    Chen J; Chen R; Feng Y; Tan M; Chen P; Wu Y
    J Biopharm Stat; 2024 Aug; 34(5):661-679. PubMed ID: 37621147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leveraging auxiliary data to improve precision in inverse probability-weighted analyses.
    Zalla LC; Yang JY; Edwards JK; Cole SR
    Ann Epidemiol; 2022 Oct; 74():75-83. PubMed ID: 35940394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating causal effects for binary outcomes using per-decision inverse probability weighting.
    Bao Y; Bell L; Williamson E; Garnett C; Qian T
    Biostatistics; 2024 Jul; ():. PubMed ID: 39078115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simple, doubly robust, efficient estimator for survival functions using pseudo observations.
    Wang J
    Pharm Stat; 2018 Feb; 17(1):38-48. PubMed ID: 29094501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical inference for data-adaptive doubly robust estimators with survival outcomes.
    Díaz I
    Stat Med; 2019 Jul; 38(15):2735-2748. PubMed ID: 30950107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toward a curse of dimensionality appropriate (CODA) asymptotic theory for semi-parametric models.
    Robins JM; Ritov Y
    Stat Med; 1997 Jan 15-Feb 15; 16(1-3):285-319. PubMed ID: 9004398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjustment for Baseline Covariates to Increase Efficiency in RCTs with Binary Endpoint: A Comparison of Bayesian and Frequentist Approaches.
    Berchialla P; Sciannameo V; Urru S; Lanera C; Azzolina D; Gregori D; Baldi I
    Int J Environ Res Public Health; 2021 Jul; 18(15):. PubMed ID: 34360051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical methods for incomplete data: Some results on model misspecification.
    McIsaac M; Cook RJ
    Stat Methods Med Res; 2017 Feb; 26(1):248-267. PubMed ID: 25063681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intervention treatment distributions that depend on the observed treatment process and model double robustness in causal survival analysis.
    Wen L; Marcus JL; Young JG
    Stat Methods Med Res; 2023 Mar; 32(3):509-523. PubMed ID: 36597699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relative performance of targeted maximum likelihood estimators.
    Porter KE; Gruber S; van der Laan MJ; Sekhon JS
    Int J Biostat; 2011; 7(1):. PubMed ID: 21931570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generalized mean residual life models for survival data with missing censoring indicators.
    Li W; Ma H; Faraggi D; Dinse GE
    Stat Med; 2023 Feb; 42(3):264-280. PubMed ID: 36437483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smoothed Rank Regression for the Accelerated Failure Time Competing Risks Model with Missing Cause of Failure.
    Qiu Z; Wan ATK; Zhou Y; Gilbert PB
    Stat Sin; 2019 Jan; 29(1):23-46. PubMed ID: 30740005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.